STOCK TITAN
  1. Home
  2. Sec-filings
  3. BCAX
  4. [SCHEDULE 13G] Bicara Therapeutics Inc. SEC Filing

[SCHEDULE 13G] Bicara Therapeutics Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Stock BCAX logo
Bicara Therapeutics

NASDAQ:BCAX

BCAX Rankings

#3052 Ranked by Market Cap
N/A Ranked by Dividends

BCAX Latest News

Aug 27, 2025
Bicara Therapeutics to Participate in Upcoming Investor Conferences
Aug 12, 2025
Bicara Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
Jul 31, 2025
Rice Biotech Launch Pad welcomes Carolyn Ng to external advisory board
Jun 3, 2025
Bicara Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
Jun 1, 2025
Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025

BCAX Latest SEC Filings

Aug 14, 2025
[SCHEDULE 13G/A] Bicara Therapeutics Inc. SEC Filing
Aug 12, 2025
[10-Q] Bicara Therapeutics Inc. Quarterly Earnings Report
Aug 12, 2025
[8-K] Bicara Therapeutics Inc. Reports Material Event
Jul 31, 2025
[SCHEDULE 13G/A] Bicara Therapeutics Inc. SEC Filing
Jul 17, 2025
[SCHEDULE 13G/A] Bicara Therapeutics Inc. SEC Filing

BCAX Stock Data

651.48M
43.93M
12.23%
93.86%
10.25%
Biotechnology
Pharmaceutical Preparations
Link
United States
BOSTON